20/08/2009
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’), (AIM:RGT) is pleased to announce that it has placed with existing shareholders 3,200,000 shares at 3p per share raising £96,000 before expenses for general working capital purposes.
The 3,200,000 new ordinary shares, which will represent 10.25 per cent of the enlarged issued share capital of the Company (31,229,882 ordinary shares), will rank pari passu in all respects with the existing ordinary shares in the Company.
Percy Lomax Chairman and Chief Executive commented:
‘So far this year ReGen has raised £493,185. This demonstrates investor confidence in the Company as we roll-out Colostrinin™ worldwide. A further significant step in this direction was seen yesterday when a test marketing agreement was signed with PRG Nutraceuticals for distribution of Colostrinin™ in the UK. The Company continues to expect to achieve sustainable profitability in 2010′.
Application has been made to the London Stock Exchange for the new ordinary shares to be admitted to trading on AIM and admission is expected to commence on or around 25 August 2009.
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David Securities Limited
Tel: 020 7448 9820